David Mott was appointed non exec of Shire plc (SHP 1015p) in October 2007.

He said then “Shire is one of the most interesting companies in the industry with an impressive recent track record of launches and an equally exciting pipeline. I’m very pleased to be joining the Shire team at this point in the Company’s development.”

On Monday, he bought 15,000 shares at 998p, spending £150k. This was his first investment in Shire.

As you’ll see from his bio, Mott is on the Astra Zeneca senior executive management team, having previously been CEO of Medimmune.

One to watch.

For all followthedirectors articles on Shire click here.